J
Janos L. Tanyi
Researcher at University of Pennsylvania
Publications - 127
Citations - 6214
Janos L. Tanyi is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 35, co-authored 111 publications receiving 4672 citations. Previous affiliations of Janos L. Tanyi include Harvard University & RWTH Aachen University.
Papers
More filters
Journal ArticleDOI
Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers
Xiaohui Yan,Xiaohui Yan,Zhongyi Hu,Yi Feng,Xiaowen Hu,Jiao Yuan,Sihai Dave Zhao,Youyou Zhang,Lu Yang,Lu Yang,Weiwei Shan,Weiwei Shan,Qun He,Lingling Fan,Lingling Fan,Lana E. Kandalaft,Lana E. Kandalaft,Janos L. Tanyi,Chunsheng Li,Chao-Xing Yuan,Dongmei Zhang,Dongmei Zhang,Huiqing Yuan,Keqin Hua,Yiling Lu,Dionyssios Katsaros,Qihong Huang,Kathleen T. Montone,Yi Fan,George Coukos,Jeff Boyd,Anil K. Sood,Timothy R. Rebbeck,Gordon B. Mills,Chi V. Dang,Lin Zhang +35 more
TL;DR: A comprehensive analysis of lncRNA alterations at transcriptional, genomic, and epigenetic levels in 5,037 human tumor specimens across 13 cancer types from The Cancer Genome Atlas suggests that the expression and dysregulation of lNCRNAs are highly cancer type specific compared with protein-coding genes.
Journal ArticleDOI
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
Denarda Dangaj,Marine Bruand,Alizée J. Grimm,Catherine Ronet,David Barras,Priyanka Duttagupta,Evripidis Lanitis,Jaikumar Duraiswamy,Janos L. Tanyi,Fabian Benencia,Jose R. Conejo-Garcia,Hena R. Ramay,Kathleen T. Montone,Daniel J. Powell,Phyllis A. Gimotty,Andrea Facciabene,Donald G. Jackson,Jeffrey S. Weber,Scott J. Rodig,Stephen Hodi,Lana E. Kandalaft,Melita Irving,Lin Zhang,Periklis G. Foukas,Sylvie Rusakiewicz,Mauro Delorenzi,Mauro Delorenzi,George Coukos +27 more
TL;DR: The cooperation between tumor-derived CCL5 and IFN-γ-inducible CXCR3 ligands secreted by myeloid cells is key for orchestrating T cell infiltration in immunoreactive and immunoresponsive tumors.
Journal ArticleDOI
A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer
Xiaowen Hu,Yi Feng,Dongmei Zhang,Dongmei Zhang,Sihai Dave Zhao,Zhongyi Hu,Joel Greshock,Youyou Zhang,Lu Yang,Lu Yang,Xiaomin Zhong,Xiaomin Zhong,Li-Ping Wang,Stephanie Jean,Chunsheng Li,Qihong Huang,Dionyssios Katsaros,Kathleen T. Montone,Janos L. Tanyi,Yiling Lu,Jeff Boyd,Katherine L. Nathanson,Hongzhe Li,Gordon B. Mills,Lin Zhang +24 more
TL;DR: This work has identified an oncogene, focally amplified lncRNA on chromosome 1 (FAL1), whose copy number and expression are correlated with outcomes in ovarian cancer, and FAL1-specific siRNAs significantly inhibit tumor growth in vivo.
Journal ArticleDOI
Lysophosphatidic acid is a bioactive mediator in ovarian cancer
Xianjun Fang,Michèl Schummer,Muling Mao,Shuangxing Yu,Fazal H. Tabassam,Ramona Swaby,Yutaka Hasegawa,Janos L. Tanyi,Ruthie Lapushin,Astrid Eder,Robert B. Jaffe,Jim Erickson,Gordon B. Mills +12 more
TL;DR: Evidence that implicates LPA in the pathophysiology of human ovarian cancer and likely other types of human malignancies is summarized.
Journal ArticleDOI
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Janos L. Tanyi,Sara Bobisse,Eran Ophir,Sandra Tuyaerts,Annalisa Roberti,Raphael Genolet,Petra Baumgartner,Brian Stevenson,Christian Iseli,Denarda Dangaj,Brian J. Czerniecki,Aikaterini Semilietof,Julien Racle,Julien Racle,Alexandra Michel,Ioannis Xenarios,Cheryl Lai-Lai Chiang,Dimitri S. Monos,Drew A. Torigian,Harvey L. Nisenbaum,Olivier Michielin,Olivier Michielin,Carl H. June,Bruce L. Levine,Daniel J. Powell,David Gfeller,David Gfeller,Rosemarie Mick,Urania Dafni,Vincent Zoete,Vincent Zoete,Alexandre Harari,George Coukos,George Coukos,Lana E. Kandalaft,Lana E. Kandalaft +35 more
TL;DR: It is concluded that the use of oxidized whole-tumor lysate DC vaccine is safe and effective in eliciting a broad antitumor immunity, including private neoantigens, and warrants further clinical testing.